Frontiers in Psychiatry
December 23, 2021
A. Fiorentini, Filippo Cantù, Camilla Crisanti et al.
123 citations
Background: On the current psychopharmacological panorama, the variety of substances able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic episodes are classified according to the major category of symptoms: positive, negative, or cognitive psychotic episodes. On one hand, the abuse of methamphetamines, cannabis, and cocaine plays a big role in increasing the...
BJPsych Open
December 23, 2021
Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al.
180 citations
Background In the past two decades, subanaesthetic doses of ketamine have been demonstrated to have rapid and sustained antidepressant effects, and accumulating research has demonstrated ketamine's therapeutic effects for a range of psychiatric conditions. Aims In light of these findings surrounding ketamine's psychotherapeutic potential, we systematically review the extant evidence on...
Current Topics in Medicinal Chemistry
December 2, 2021
Teresa Reynolds de Sousa, João Rema, Sérgio Machado et al.
7 citations
Background: The therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between efficacy and side effects. Objective: This work aims to review current evidence regarding the potential contribution of psychedelics and hallucinogens to the discovery of new drugs for treating different psychiatric disorders. Discussion:...
International Journal of Drug Policy
December 1, 2021
David B. Yaden, Andrea P Berghella, Paul S. Regier et al.
Several pilot studies have provided evidence supporting the potential of classic psychedelics like psilocybin in the treatment of substance use disorders (SUDs). If larger trials confirm efficacy, classic psychedelic-assisted psychotherapy may eventually be integrated into existing addiction treatments such as cognitive behavioral therapy, contingency management, and medication-assisted...
Pain Medicine
November 26, 2021
Mohammed M Faraj, Nina M Lipanski, Austin Morales et al.
Standard of care for opioid use disorder (OUD) includes medication and counseling. However, there is an unmet need for complementary approaches to treat OUD patients coping with pain; furthermore, few studies have probed neurobiological features of pain or its management during OUD treatment. This preliminary study examines neurobiological and behavioral effects of a virtual reality-based...
Journal of Ethnopharmacology
November 22, 2021
Bruno Gianfratti, Ricardo Tabach, Marna Eliana Sakalem et al.
23 citations
Ethnopharmacological relevanceAyahuasca, a psychoactive beverage prepared from Banisteriopsis caapi and Psychotria viridis, is originally used by Amazon-based indigenous and mestizo groups for medicinal and ritualistic purposes. Nowadays, ayahuasca is used in religious and shamanic contexts worldwide, and preliminary evidence from preclinical and observational studies suggests therapeutic...
Alcoholism & Drug Abuse Weekly
November 19, 2021
Gary Enos
With nicotine being one of the most addictive substances and the available treatments for nicotine addiction leading to no better than a 30% success rate, it's no wonder that a newly announced multisite study of the psychedelic psilocybin for smoking cessation is generating excitement. While taking care not to oversell the potential of this strategy, those involved with the research hope at...
Science Advances
November 17, 2021
Marcus W. Meinhardt, Simone Pfarr, Grégory Fouquet et al.
92 citations
Alcohol-induced mGluR2 deficits are restored by psilocybin, resulting in a rescue of pathological behaviors in alcoholism.
Canadian Medical Association Journal
November 14, 2021
Greg Basky
7 citations
Research interest in the therapeutic use of psilocybin, or "magic mushrooms," is growing alongside a "wild west" of dispensaries in Canada and the United States. The past decade has seen a revival of research exploring the clinical use of psychedelics in treating depression, addiction,
The International Journal of Neuropsychopharmacology
November 12, 2021
Javier Orihuel, Roberto Capellán, David Roura-Martínez et al.
Cannabis exposure during adolescence is associated with emotional and motivational alterations that may entail an enhanced risk of developing psychiatric disorders. In rodent models, exposure to cannabinoids during adolescence leads to increased self-administration of opiates and cocaine, however, the psychological and neural mechanisms and the sex-specificity of this phenomenon are largely...
Psychological Thought
October 30, 2021
Derek Botha
2 citations
This article proposes alternative understandings of certain structuralist informed (Diagnostic and Statistical Manual of Mental Disorders - DSM-IIIrd to 5th Eds.) configurations of mental disorders. Life’s negative discourses and the mind’s captive responses present a “general theory of mental suffering” which phenomena are classified as modernist, DSM mental disorders, such as addictions,...
Clinical Psychopharmacology and Neuroscience
October 25, 2021
Jaber Alizadehgoradel, Saeed Imani, Vahid Nejati et al.
28 citations
OBJECTIVE: Transcranial direct current stimulation (tDCS) and mindfulness practices have been proposed as a potential approach to improve executive functions (EFs) and reduce craving in persons with substance use disorders. Based on the neural mechanisms of action of each of these interventions, the combination of both non-pharmacological interventions might have additive effects. In the...
Cochrane Database of Systematic Reviews
October 20, 2021
Simon B. Goldberg, Brian Pace, Matas Griskaitis et al.
Background: Substance use disorders (SUDs) are highly prevalent and associated with a substantial public health burden. Although evidence-based interventions exist for treating SUDs, many individuals remain symptomatic despite treatment, and relapse is common.Mindfulness-based interventions (MBIs) have been examined for the treatment of SUDs, but available evidence is mixed. Objectives: To...
Sexual & Relationship Therapy
October 20, 2021
Dee Dee Goldpaugh
22 citations
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, and substance use disorders. These medicines have also been used in sacred, ritual settings for, in some cases, centuries. Often referred to as entheogens (meaning “creating the divine within”), psychedelic plant medicines such as psilocybin...
British Journal of Pharmacology
October 1, 2021
Kwang-Hyun Hur, Seong-Eon Kim, Shi-Xun Ma et al.
Methoxphenidine is a dissociative-based novel psychoactive designer drug. Although fatal accidents from methoxphenidine abuse have been reported, recreational use of the drug continues. We aim to provide scientific supportfor legal regulation of recreational abuse of methoxphenidine by demonstrating its the pharmacological action. Addictive potential of methoxphenidine was examined using...
Alcoholism & Drug Abuse Weekly
September 24, 2021
Alison Knopf
First it was the plant, cannabis. How could this be made into a saleable profit‐making commodity when it grows in the ground? Witness the marijuana (a chemical from the plant) industry, which lobbied to make sure laws in states that legalized it banned people from growing more than a few plants.
Pajouhan Scientific Journal
September 1, 2021
M. Ahmadi, Zahra Nikomanesh, A. Farnam
Background and Objectives: One of the most modern addictive behaviors is the phenomenon of Internet addiction, which is associated with criteria, such as withdrawal, depression, loneliness, and anxiety. This study aimed to determine the effectiveness of stress-based mindfulness therapy on the students' feelings of loneliness and Internet addiction. Materials and Methods: This quasi-experimental...
Journal of Psychoactive Drugs
August 19, 2021
Brian S. Barnett, Yvan Beaussant, Franklin King et al.
64 citations
Despite resurgent interest in psychedelic-assisted therapy, our insights into psychiatrists' knowledge and opinions about medicinal psychedelic applications are surprisingly narrow. Therefore, we anonymously surveyed psychiatrists attending psychedelic didactic presentations at two national meetings about these issues using a 26-item questionnaire. Response rate was 40.20% (106/264)....
Addiction
August 12, 2021
Wayne Hall, Michael Farrell
8 citations
The history of research on the use of psychedelic drugs to treat alcohol dependence in the 1950s and 1960s suggests the need for caution in their proposed clinical use. Since 2006 there has been a revival of interest in using psychedelics to treat depression and post-traumatic stress disorders [1] and the addictions [2]. What lessons may we glean from research in the 1950s and 1960s on the use...
L'Encephale
August 1, 2021
Lucie Berkovitch, Bruno Romeo, Laurent Karila et al.
25 citations
Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...